The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 17, 2025

Filed:

Jun. 15, 2023
Applicant:

Arcutis Biotherapeutics, Inc., Westlake Village, CA (US);

Inventors:

David Reuben Berk, Westlake Village, CA (US);

Patrick Eugene Burnett, Westlake Village, CA (US);

Saori Kato, Westlake Village, CA (US);

David W. Osborne, Fort Collins, CO (US);

Assignee:

ARCUTIS BIOTHERAPEUTICS, INC., Westlake Village, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/44 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/27 (2006.01); A61K 31/343 (2006.01); A61K 31/4174 (2006.01); A61K 31/4418 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/60 (2006.01); A61K 33/04 (2006.01); A61K 45/06 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01);
U.S. Cl.
CPC ...
A61K 31/44 (2013.01); A61K 9/0014 (2013.01); A61K 31/137 (2013.01); A61K 31/27 (2013.01); A61K 31/343 (2013.01); A61K 31/4174 (2013.01); A61K 31/4418 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/60 (2013.01); A61K 33/04 (2013.01); A61K 45/06 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01);
Abstract

The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungispp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness,, and/or. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.


Find Patent Forward Citations

Loading…